Deciphera Pharmaceuticals, Inc., a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST. The company is also developing vimseltinib, an orally administered, potent, and highly selective switch-control kinase inhibitor of colony stimulating factor 1 receptor (CSF1R) for the treatment of tenosynovial giant cell tumor (TGCT); and DCC-3116 to treat RAS/RAF mutant cancers that is in the preclinical-stage. Deciphera Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Waltham, Massachusetts. As of June 11, 2024, Deciphera Pharmaceuticals, Inc. operates as a subsidiary of Ono Pharmaceutical Co., Ltd.
| 38.75 | |
| 38.5 | |
| - | |
| 38.78 | |
| 38.46 | |
| 10.475-39.7 | |
| 2 056 M | |
| 86 476 K | |
| 175 M | |
| 0.184 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
Deciphera Pharmaceuticals, Inc. (DCPH) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended December 2023. This widely-known co...
While it may not be enough for some shareholders, we think it is good to see the Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) share price up 20% in a single quarter. But over the last three years we'...
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
